Association of pharmacist-led electronic patient-reported outcome monitoring on physician–pharmacist collaborations and pharmaceutical interventions in early breast cancer: a retrospective cohort study

Background Electronic patient-reported outcome (ePRO) monitoring facilitates symptom detection during cancer treatment; however, evidence regarding how pharmacist-led ePRO monitoring is associated with pharmacist practice processes remains limited. This study examined the association of pharmacist-led ePRO monitoring with documented physician–pharmacist collaborations and pharmaceutical interventions during neoadjuvant chemotherapy (NAC) for early-stage breast cancer. Methods This single-center study was a secondary retrospective analysis of the same patient cohort as our previous study and included 96 patients who received NAC for early-stage breast cancer, of whom 43 underwent pharmacist-led ePRO monitoring and 53 received usual care. The primary outcome was the number of documented physician–pharmacist collaborations, and the main secondary outcome was the number of prescription proposals. Adjusted count regression analyses were performed using negative binomial regression for physician–pharmacist collaborations and Poisson regression with robust standard errors for prescription proposals. The number of chemotherapy cycles was incorporated as an offset to account for differences in treatment exposure. Results Among the 96 patients, 43 (44.8%) initiated ePRO monitoring. Among these patients, the median number of ePRO entries during NAC was 74 (IQR, 62–85), and the median reporting completion rate was 71.4% (IQR, 60.1–81.5). Physician–pharmacist collaborations and prescription proposals were more frequent in the ePRO group than in the usual care group (1.53 ± 1.44 vs. 0.38 ± 0.77 and 1.30 ± 1.01 vs. 0.37 ± 0.76, respectively; both p < 0.001). After adjustment for age, ECOG performance status, chemotherapy regimen, and treatment exposure, ePRO monitoring was associated with higher rates of physician–pharmacist collaboration (adjusted incidence rate ratio [IRR], 4.60; 95% CI, 2.45–8.64; p < 0.001) and prescription proposals (adjusted IRR, 3.33; 95% CI, 1.91–5.80; p < 0.001). Conclusions Pharmacist-led ePRO monitoring was associated with higher rates of documented physician–pharmacist collaboration and prescription proposals during NAC for early-stage breast cancer, even after accounting for differences in treatment exposure. These findings suggest that integrating patient-reported symptom monitoring into pharmacist practice may provide additional opportunities for symptom-triggered communication and pharmaceutical intervention. Further prospective studies are needed to determine whether these associations translate into improvements in quality of care or patient outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2026-11-18
DOI
https://doi.org/10.1186/s40780-026-00645-4
Primary Topic
Pharmacy and Medical Practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of pharmacist-led electronic patient-reported outcome monitoring on physician–pharmacist collaborations and pharmaceutical interventions in early breast cancer: a retrospective cohort study

Arisa Kawakami, Yoshiharu Mitsunaga, Natsumi Nomoto, Tamaki Watanabe et al.
6 links
Journal of Pharmaceutical Health Care and Sciences
Pharmacy and Medical Practices
article

Association of pharmacist-led electronic patient-reported outcome monitoring on physician–pharmacist collaborations and pharmaceutical interventions in early breast cancer: a retrospective cohort study

Arisa Kawakami, Yoshiharu Mitsunaga, Natsumi Nomoto, Tamaki Watanabe, Nobuhiro Yasuno, Yukie Nagase, Yuki Takei, Yuko Miyake, Mizuki Kawashima, 島 忠光, Isao Teshima, Atsufumi Nomoto
article en

Abstract

Background Electronic patient-reported outcome (ePRO) monitoring facilitates symptom detection during cancer treatment; however, evidence regarding how pharmacist-led ePRO monitoring is associated with pharmacist practice processes remains limited. This study examined the association of pharmacist-led ePRO monitoring with documented physician–pharmacist collaborations and pharmaceutical interventions during neoadjuvant chemotherapy (NAC) for early-stage breast cancer. Methods This single-center study was a secondary retrospective analysis of the same patient cohort as our previous study and included 96 patients who received NAC for early-stage breast cancer, of whom 43 underwent pharmacist-led ePRO monitoring and 53 received usual care. The primary outcome was the number of documented physician–pharmacist collaborations, and the main secondary outcome was the number of prescription proposals. Adjusted count regression analyses were performed using negative binomial regression for physician–pharmacist collaborations and Poisson regression with robust standard errors for prescription proposals. The number of chemotherapy cycles was incorporated as an offset to account for differences in treatment exposure. Results Among the 96 patients, 43 (44.8%) initiated ePRO monitoring. Among these patients, the median number of ePRO entries during NAC was 74 (IQR, 62–85), and the median reporting completion rate was 71.4% (IQR, 60.1–81.5). Physician–pharmacist collaborations and prescription proposals were more frequent in the ePRO group than in the usual care group (1.53 ± 1.44 vs. 0.38 ± 0.77 and 1.30 ± 1.01 vs. 0.37 ± 0.76, respectively; both p < 0.001). After adjustment for age, ECOG performance status, chemotherapy regimen, and treatment exposure, ePRO monitoring was associated with higher rates of physician–pharmacist collaboration (adjusted incidence rate ratio [IRR], 4.60; 95% CI, 2.45–8.64; p < 0.001) and prescription proposals (adjusted IRR, 3.33; 95% CI, 1.91–5.80; p < 0.001). Conclusions Pharmacist-led ePRO monitoring was associated with higher rates of documented physician–pharmacist collaboration and prescription proposals during NAC for early-stage breast cancer, even after accounting for differences in treatment exposure. These findings suggest that integrating patient-reported symptom monitoring into pharmacist practice may provide additional opportunities for symptom-triggered communication and pharmaceutical intervention. Further prospective studies are needed to determine whether these associations translate into improvements in quality of care or patient outcomes.

Journal of Pharmaceutical Health Care and Sciences
Teikyo University Hospital (JP), Teikyo University (JP)
Good health and well-being
Pharmacy and Medical Practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon